Institute for Molecular Medicine Finland (FIMM) HiLIFE, University of Helsinki

An Ecosystem for Genetic Discovery and Clinical Translation
Finland has a well-established role at the cutting edge of genomics research. With a relatively isolated population, support from the government, and comprehensive health registry, genomics research has yielded numerous results over the years, particularly in the prediction and management of Mendelian diseases.
Leading this research is the Institute for Molecular Medicine Finland - or FIMM - which was established in 2006. FIMM attracts researchers from all over the world based on its facilities, wide-ranging expertise, and comprehensive genomic data. By combining patient data from the national registry with genetic information from one of the largest BioBanks in the world, researchers are able to examine a wide range of genetic diseases. In order to fully exploit this wealth of data FIMM is also developing the use of machine learning and other tools at the FIMM Technology Centre - making FIMM one of the best places in the world to do genomic research.
At the same time, through close collaboration with hospitals across the country, FIMM is translating this important work into practice. The GeneRISK study looked at the impact knowledge about genetic risk has on behaviour. Over 7000 patients were provided with information about their risk of cardiovascular disease, using a tool called KardioKompassi®. 18 months later, 17% of smokers had given up, and weight loss had been achieved by 13.7% - with more recruits and follow-ups for the next 20 years, this study is ongoing.
With a wealth of data, collaboration across the Finnish health system, and state-of-the-art technology, FIMM is working to form the basis of the next-generation of precision genomics, from drug development to cancer modelling. Driving this is FinnGen, a project aiming to collect data on 500,000 Finnish people, combine it with health care data, and gain a comprehensive understanding of diseases across the population, including Alzheimer’s and Heart Disease. With a custom-designed array and collaborations with public healthcare and pharmaceutical companies, FinnGen will be one of the world’s most important genomics projects.
FinnGen and the rest of the work done at FIMM will open a new world of genetic research allowing researchers to identify a huge number of new genes, facilitating the development of new interventions and new therapies. With FIMM providing a unique ecosystem for genetic discovery and research, it will remain a great home for up and coming genomics researchers from around the world for years to come.